SYS-CON MEDIA Authors: Trevor Parsons, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

SK3 Group (OTC Pink: SKTO) Is Seeking to Survey Qualified California Medical Marijuana Patients for Its Soon to Be Released Dharmanol Citrolene Capsules, Providing Free Samples for a Limited Time

LOS ANGELES, CA -- (Marketwired) -- 02/28/14 -- Medical Greens, a subsidiary of SK3 Group (OTC Pink: SKTO) is seeking qualified California medical marijuana patients to receive a free sample of its new, non-psychoactive medical cannabis product, Dharmanol Citrolene, developed by its Berkeley Bio-Organic Research Laboratory.

Containing many of the medicinal elements of medical marijuana in their non-psychoactive form, Dharmanol Citrolene provides many of the benefits that scientists are ascribing to medical cannabis, without the high associated with eating or smoking marijuana.

Dharmanol Citrolene contains CBD, a non-psychoactive "chemical cousin" to THC, the element in marijuana that makes people high or stoned. In addition, it contains phyto-cannabinoids in their non-psychoactive carboxylate form. It also contains d-limonene, a medicinal element found in cannabis, known as a terpene.

D-limonene has been shown to have a relaxing, anti-anxiety, anti-spasmodic effect. This is because it binds to the same receptors in the human body as do the pharmaceutical synthetics Valium and Xanax. Dharmanol Citrolene contains a healthy dose of organically-sourced d-limonene. Although the d-limonene used in Dharmanol Citrolene is chemically identical to that produced by the cannabis/hemp plant, it is actually sourced from the rind of citrus fruits.

Interestingly, research has shown d-limonene to have many properties that are similar to cannabis in their interaction with cancer. Sloan Kettering Cancer Center lists 19 very promising studies using this powerful natural medicine.

http://www.mskcc.org/cancer-care/herb/d-limonene.

To participate in the Company's survey, an individual must be a medical cannabis patient with a valid physician recommendation and live in the State of California in one of the zip codes currently served by Pharmajanes.com. To see if you qualify, go to the website and check out the section labeled "Dharmanol Citrolene Promotion." Starting this upcoming Wednesday, March 5, 2014, individuals requesting the promotional product during the first 30 days, while supplies last, will receive a 2-pack of the product.

Patients participating in the survey will be asked to complete a short questionnaire about their use of the product which will assist the Company in developing or improving its offerings.

Dharmanol Citrolene will be available for sale soon after that through Pharmajanes and many dispensaries throughout California.

Mr. Artemus Mayor, President of SK3 Group said, "Now that our Pharmajanes site is up and running, and we are filling orders for our Dharmanol product, we are pleased to be initiating distribution for this important product through our Pharmajanes platform. While Dharmanol Citrolene will only be available to participants in the promotion for the next several weeks, we intend to have the product available to all qualified patients soon, either through our Pharmajanes platform, or through their local dispensary."

About AEGY
PharmaJanes™ is an online ordering platform allowing medical marijuana patients to order, process and pay for their authorized needs, in a simple, safe and secure ordering and payment interface. Simple Prepay is a merchant payment solution developed to offer a convenient payment solution to medical cannabis dispensaries, collectives, and delivery services. PharmaJanes also is the exclusive online marketing platform for Medical Greens, a subsidiary of SK3 Group, Inc. (OTC Pink: SKTO).

About SKTO
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.